AngioDynamics, Inc.

AngioDynamics, Inc. is a global medical technology company that designs, manufactures, and sells a broad range of minimally invasive medical devices. Established in 1988 as a division of E-Z-EM, Inc., the company became an independent publicly traded entity in 2004. Its mission is to improve patient outcomes by being a leader in innovative, proprietary therapeutic devices used by interventionalists and surgeons for the minimally invasive treatment of peripheral vascular disease, tumor therapy, and other non-vascular conditions. The company's corporate headquarters are located in Latham, New York, United States.

AngioDynamics' product portfolio focuses on three core areas: vascular access, peripheral vascular intervention, and interventional oncology. Key products include the AlphaVac System and AngioVac System for thrombus management, the NanoKnife System for soft tissue ablation in tumor therapy, and the Auryon System for peripheral arterial disease. The company also offers a variety of other devices such as SmartPort Power-Injectable Port Family, Vortex Ports, drainage catheters, guidewires, and angiographic catheters. These devices are designed to elevate the standard of care for patients in the diagnosis and treatment of cardiovascular and oncologic diseases.

Under the leadership of President and CEO Jim Clemmer, who joined in April 2016, AngioDynamics has been undergoing a strategic transformation to sharpen its focus on higher-growth Med Tech platforms. This strategy has involved streamlining its medical device business through the sale of certain product portfolios, such as PICC, midline, and tip location products to Spectrum Vascular in early 2024, and its dialysis product portfolio and BioSentry tract sealant system to Merit Medical Systems in mid-2023. The company is also consolidating its manufacturing footprint, including the closure of facilities in Warren County, NY, as part of efforts to achieve profitability by fiscal year 2027. AngioDynamics reported sustained double-digit growth in its Med Tech segment and raised its full-year fiscal 2026 guidance.